TSE:4151Pharmaceuticals
Did Kyowa Kirin's (TSE:4151) New NPM1‑Mutated AML Trial Just Reframe Its Oncology Ambitions?
Kyowa Kirin and Kura Oncology recently dosed the first patient in a Japanese Phase 2 registrational trial of ziftomenib, an oral menin inhibitor, for adults with relapsed or refractory NPM1‑mutated acute myeloid leukemia, following its prior approval in the US as KOMZIFTI.
This trial targets a genetic subtype representing around 30% of AML cases in Japan and could support Kyowa Kirin’s planned regulatory filing, while also extending the clinical footprint of a therapy already in use...